-- Second quarter revenue grew 8% year-over-year to $49.0 million
-- Life Sciences Services revenue increased 15% year-over-year
-- BioStorage/BioServices revenue grew 25% year-over-year
-- Supporting 779 global clinical trials and 22 commercially approved cell
and gene therapies (CGT) as of June 30, 2026
NASHVILLE, Tenn., Aug. 6, 2026 /PRNewswire/ -- Cryoport, Inc. $(CYRX)$ ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its second quarter (Q2) and first half (H1) of 2026.
Jerrell Shelton, CEO of Cryoport, commented, "Our revenue momentum over the past several periods continued into the second quarter, with total revenue reaching $49.0 million. Life Sciences Services revenue grew 15% year-over-year, led by 25% growth in BioStorage/BioServices revenue. Our Life Sciences Products business also generated solid results during the quarter, driven by continued demand for MVE Biological Solutions' industry-leading cryogenic systems and the successful introduction of new and innovative products.
"Total revenue from the support of commercial CGT grew 9% year-over-year to $9.4 million. The Life Science Services portion of our revenue from supporting commercial CGT grew 26% year-over-year as the number of patients treated in the community setting and on an outpatient basis continued to ramp. Total revenue for the quarter from supporting CGT clinical trials increased 12% year-over-year to $13.4 million as our customers' clinical pipelines advanced and further matured. We supported a record 779 clinical trials globally as of June 30, 2026, reflecting the strength of our industry-leading position as the CGT market continues to advance.
"Our second quarter results also reflect meaningful progress on our "pathway to profitability." Achieving positive adjusted EBITDA in the second quarter represents an important milestone in our ongoing pathway to sustainable profitability and demonstrates the value of our strategic investments and operational initiatives we have executed over the past several years. We are pleased with this accomplishment as we continue to optimize our global operations, leverage our expanding infrastructure, and benefit from the operating leverage that we anticipate will take effect as we increasingly scale and put our investments to work.
"Overall, we delivered a strong second quarter, generating growth across key revenue streams, improving profitability, and achieving an important milestone with positive adjusted EBITDA for the quarter. With our accomplishments to date, we believe that we are well positioned to further expand margins, enhance operating efficiency, and deliver sustainable, profitable long-term growth for our shareholders. We remain focused on executing our strategy, driving financial performance, and capitalizing on the significant opportunities before us. We expect upcoming growth catalysts in our business segments, represented by the expansion of our Global Supply Chain Center Network and recent launches of new products and services, will drive us to new heights in market position, growth, and productivity," concluded Mr. Shelton.
The following table presents Q2 2026 revenue compared with Q2 2025:
Cryoport, Inc. and
Subsidiaries
Revenue
----------------------- ------------- ----------- -------- ----------- ----------- --------
Three Months Ended Six Months Ended
June 30, June 30,
(unaudited) (unaudited)
(in thousands) 2026 2025 % Change 2026 2025 % Change
----------------------- ------------- ----------- -------- ----------- ----------- --------
Life Sciences Services $ 27,969 $ 24,369 15 % $ 54,867 $ 47,234 16 %
BioLogistics Solutions 22,359 19,874 13 % 44,027 38,404 15 %
----------------------- ------------- ----------- -------- ----------- ----------- --------
BioStorage/BioServices 5,610 4,495 25 % 10,840 8,830 23 %
Life Sciences Products $ 21,002 $ 21,085 0 % $ 41,902 $ 39,260 7 %
----------------------- ------------- ----------- -------- ----------- ----------- --------
Total Revenue $ 48,971 $ 45,454 8 % $ 96,769 $ 86,494 12 %
----------------------- ------------- ----------- -------- ----------- ----------- --------
BioLogistics Solutions revenue increased 13% year-over-year in Q2 2026, driven by increasing customer activity, continued commercial product development, and clinical advancement within the CGT market. BioStorage/BioServices revenue grew 25% year-over-year, reflecting strong demand for our expanded, integrated services offering, which provides seamless, secure handling of temperature-sensitive materials across our global network.
As of June 30, 2026, the number of commercial cell and gene therapies we support increased to 22 and our total clinical trial count that we support rose to 779 clinical trials worldwide, a net increase of 51 clinical trials over June 30, 2025, with 94 of these clinical trials in Phase 3. The number of trials by phase and region are as follows:
Cryoport Supported Clinical Trials by Phase
Clinical Trials June 30,
-----------------------
2024 2025 2026
Phase 1 286 304 316
-------------------------- ------- ------ ------
Phase 2 322 342 369
Phase 3 76 82 94
Total 684 728 779
-------------------------- ------- ------ ------
Cryoport Supported Clinical Trials by Region
Clinical Trials June 30,
-----------------------
2024 2025 2026
Americas 525 556 579
-------------------------- ------- ------ ------
EMEA 114 124 145
APAC 45 48 55
Total 684 728 779
-------------------------- ------- ------ ------
In Q2 2026, four of our customers filed Biologics License Applications (BLA) / Marketing Authorization Applications $(MAA)$. During the Q2 2026, Cryoport's customer, Orca Bio, received U.S. Food and Drug Administration (FDA) approval for TREGZI$(TM)$ as the first and only precision-engineered cell therapy for allogeneic stem cell transplant in the treatment of adults with hematological malignancies. Additionally, during Q2 2026, Vertex Pharmaceuticals received supplemental approval from the FDA to expand the label of CASGEVY$(R)$ for the treatment of patients aged two years and older with either sickle cell disease $(SCD)$ with recurrent vaso-occlusive crises (VOCs) or transfusion-dependent beta thalassemia (TDT). CASGEVY is the first approved gene therapy indicated for children as young as two years for both SCD and TDT. For the balance of 2026, we anticipate another 11 possible BLA/MAA applications, five possible additional new therapy approvals, and one possible additional approval for label/geographic expansion from our customer base.
Operational milestones
-- Cryoport Systems' IntegriCell(R) cryopreservation services were selected
by Verismo Therapeutics, a clinical-stage CAR T-cell therapy company
pioneering a novel multi-chain KIR-CAR platform technology for the
treatment of solid tumors (SynKIR(TM)-110) and B cell associated
disorders and malignancies (SynKIR(TM)-310).
-- Advanced toward the planned launch of BioServices operations at our
Global Supply Chain Center in Paris, France, expected in Q4 2026.
-- Continued progress toward the launch of our state-of-the-art Global
Supply Chain Center in Santa Ana, California, expected in Q4 2026.
-- Shipped first HE freezers "made in China for China" from our Chengdu,
China manufacturing facility.
Financial Highlights
On June 11, 2025, the Company completed the divestiture of its CRYOPDP specialty courier business to DHL Group. The results of CRYOPDP, a former business within Cryoport's Life Sciences Services segment, are presented as discontinued operations for all periods and are excluded from the non-GAAP financial measures in this release.
Revenue
-- Total revenue for Q2 2026 was $49.0 million, compared to $45.5 million
for Q2 2025, a year-over-year increase of 8%, or $3.5 million.
-- Life Sciences Services revenue for Q2 2026 (representing 57% of
our total revenue) was $28.0 million, compared to $24.4 million
for Q2 2025, up 15% year-over-year, including
BioStorage/BioServices revenue of $5.6 million, up 25%
year-over-year.
-- Life Sciences Products revenue for Q2 2026 (representing 43% of
our total revenue) was $21.0 million, compared to $21.1 million
for Q2 2025.
-- Total revenue for H1 2026 was $96.8 million, compared to $86.5 million
for H1 2025.
-- Life Sciences Services revenue for H1 2026 was $54.9 million,
compared to $47.2 million for H1 2025, including
BioStorage/BioServices revenue of $10.8 million, compared to $8.8
million for H1 2025.
-- Life Sciences Products revenue for H1 2026 was $41.9 million,
compared to $39.3 million for H1 2025.
Gross Margin
-- Total gross margin was 46.6% for Q2 2026, compared to 47.0% for Q2 2025.
-- Gross margin for Life Sciences Services was 49.9% for Q2 2026,
compared to 48.9% for Q2 2025.
-- Gross margin for Life Sciences Products was 42.2% for Q2 2026,
compared to 44.9% for Q2 2025.
-- Total gross margin was 46.2% for H1 2026, compared to 46.3% for H1 2025.
-- Gross margin for Life Sciences Services was 49.4% for H1 2026,
compared to 48.4% for H1 2025.
-- Gross margin for Life Sciences Products was 42.1% for H1 2026,
compared to 43.7% for H1 2025.
Operating Costs and Expenses
-- Operating costs and expenses were $32.9 million for Q2 2026, compared to
$31.0 million for Q2 2025. Operating costs and expenses were $64.4
million for H1 2026, compared to $56.9 million for H1 2025.
Loss from Continuing Operations
-- Loss from continuing operations was $8.3 million for Q2 2026, compared to
a loss of $12.0 million for Q2 2025. Loss from continuing operations was
$17.7 million for H1 2026, compared to a loss of $18.8 million for H1
2025.
Net Income (Loss) -- including Discontinued Operations
-- Net loss was $8.3 million for Q2 2026, compared to net income of $108.9
million for Q2 2025. Net loss for H1 2026 was $18.8 million, compared to
net income of $96.9 million for H1 2025. Net income for Q2 2025 and H1
2025 was primarily driven by the sale of our CRYOPDP specialty courier
business during Q2 2025, which contributed $120.9 million and $115.6
million, net of taxes, respectively, to income from discontinued
operations.
-- Net loss attributable to common stockholders for Q2 2026 was $10.3
million, or $0.20 per share. Net loss attributable to common stockholders
for H1 2026 was $22.8 million, or $0.45 per share. This compares to net
income attributable to common stockholders of $106.9 million, or $2.13
per share, and $92.9 million, or $1.85 per share, for Q2 2025 and H1
2025, respectively.
Adjusted EBITDA from Continuing Operations
-- Adjusted EBITDA from continuing operations was $0.4 million for Q2 2026,
compared to a negative $0.9 million for Q2 2025. Adjusted EBITDA from
continuing operations for H1 2026 was a negative $0.2 million, compared
to a negative $3.7 million for H1 2025.
Cash, Cash equivalents, and Short-Term Investments
-- Cryoport held $396.7 million in cash, cash equivalents, and short-term
investments as of June 30, 2026.
Note: All reconciliations of GAAP to adjusted (non-GAAP) figures above are detailed in the reconciliation tables included later in the press release.
Additional Information
Further information on Cryoport's financial results is included in the attached condensed consolidated balance sheets and statements of operations, and additional explanations of Cryoport's financial performance are provided in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which is expected to be filed with the Securities and Exchange Commission ("SEC") on August 6, 2026. Additionally, the full report will be available in the SEC Filings section of the Investor Relations section of Cryoport's website at www.cryoportinc.com.
Earnings Conference Call Information
IMPORTANT INFORMATION: In addition to the earnings release, a document titled "Cryoport Second Quarter 2026 in Review," providing a review of Cryoport's business update, will be issued at 4:05 p.m. ET on Thursday, August 6, 2026. The document is designed to be read in advance of the questions and answers conference call and will be accessible at https://ir.cryoportinc.com/news-events/ir-calendar.
Cryoport management will host a conference call at 5:00 p.m. ET on August 6, 2026. The conference call will be in the format of a questions and answers session and will address any queries investors have regarding the Company's reported results. A slide deck will accompany the call.
Conference Call Information
Date: Thursday, August 6, 2026
Time: 5:00 p.m. ET
Dial-in numbers: 1-800-717-1738 (U.S.), 1-646-307-1865 (International)
Confirmation code: Request the "Cryoport Call" or Conference ID: 1142151
Live webcast: 'Investor Relations' section at www.cryoportinc.com or
click here. Please allow 10 minutes prior to the call to
visit this site to download and install any necessary
audio software.
The questions and answers call will be recorded and available approximately three hours after completion of the live event in the Investor Relations section of the Company's website at www.cryoportinc.com for a limited time. To access the replay of the questions and answers click here. A dial-in replay of the call will also be available to those interested, until August 13, 2026. To access the replay, dial 1-844-512-2921 (United States) or 1-412-317-6671 (International) and enter replay entry code: 1142151#.
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine. We support biopharmaceutical companies, contract manufacturers (CDMOs), contract research organizations (CROs), developers, and researchers with a comprehensive suite of services and products designed to minimize risk and maximize reliability across the temperature-controlled supply chain for the life sciences. Our integrated supply chain platform includes the Cryoportal(R) Logistics Management Platform, advanced temperature-controlled packaging, informatics, specialized BioLogistics, BioStorage, BioServices, cryopreservation services, and cryogenic systems, which in varying combinations deliver end-to-end solutions that meet the rigorous demands of the life sciences. With innovation, regulatory compliance, and agility at our core, we are "Enabling the Future of Medicine(TM)."
Headquartered in Nashville, Tennessee, our company maintains a strong global presence with operations across the Americas, EMEA, and APAC.
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at https://x.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding the Company's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to the Company's industry, business, long-term growth prospects, plans, strategies, acquisitions, future financial results and financial condition, such as the Company's outlook and guidance for full-year 2026 revenue and the related assumptions and factors expected to drive revenue, projected growth trends in the markets in which the Company operates, the Company's plans and expectations regarding the launch of new products and services, such as the expected timing and benefits of such products and services launches, the Company's expectations about future benefits of its acquisitions, and anticipated regulatory filings, approvals, label/geographic expansions or moves to earlier lines of treatment approved with respect to the products of the Company's clients. Forward-looking statements also include those related to the Company's plans regarding its Global Supply Chain Centers, including expected timing of future openings, the Company's anticipation that it will benefit from its operating leverage, the Company's belief that it is well positioned to further expand margins, enhance operating efficiency and deliver sustainable, profitable long-term growth for its shareholders, and the Company's expectation that upcoming growth catalysts in its business segments will drive the Company to new heights in market position, growth, and productivity. It is important to note that the Company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effects of changing economic and geopolitical conditions, such as those resulting from the war with Iran, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in the Company's cash flow, market acceptance risks, the effects of tariffs and other trade restrictions, and technical development risks. The Company's business could be affected by other factors discussed in the Company's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, the Company disclaims any obligation and does not undertake to update or revise any forward-looking statements in this press release.
Cryoport, Inc.
and
Subsidiaries
Condensed
Consolidated
Statements of
Operations
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Three Months Ended Six Months Ended
June 30, June 30,
(unaudited) (unaudited)
(in thousands,
except share
and per share
data) 2026 2025 2026 2025
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Revenue
Life Sciences
Services
revenue $ 27,969 $ 24,369 $ 54,867 $ 47,234
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Life Sciences
Products
revenue 21,002 21,085 41,902 39,260
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Total revenue 48,971 45,454 96,769 86,494
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Cost of
revenue:
Cost of
services
revenue 14,008 12,449 27,755 24,369
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Cost of
products
revenue 12,139 11,628 24,277 22,107
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Total cost of
revenue 26,147 24,077 52,032 46,476
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Gross margin 22,824 21,377 44,737 40,018
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Operating costs
and expenses:
Selling,
general and
administrative 28,011 26,908 55,631 48,809
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Engineering and
development 4,852 4,118 8,759 8,052
Total operating
costs and
expenses: 32,863 31,026 64,390 56,861
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Loss from
operations (10,039) (9,649) (19,653) (16,843)
Other income
(expense):
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Investment
income 3,132 1,466 6,222 3,039
Interest
expense (518) (618) (950) (1,201)
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Other expense,
net (325) (2,939) (2,693) (3,239)
Loss before
provision for
income taxes (7,750) (11,740) (17,074) (18,244)
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Provision for
income taxes (505) (274) (613) (508)
Loss from
continuing
operations $ (8,255) $ (12,014) $ (17,687) $ (18,752)
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Income (loss)
from
discontinued
operations,
net - 120,883 (1,112) 115,640
Net income
(loss) $ (8,255) $ 108,869 $ (18,799) $ 96,888
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Paid-in-kind
dividend on
Series C
convertible
preferred
stock (2,000) (2,000) (4,000) (4,000)
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Net income
(loss)
attributable
to common
stockholders $ (10,255) $ 106,869 $ (22,799) $ 92,888
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Net income
(loss) per
share
attributable
to common
stockholders -
basic and
diluted $ (0.20) $ 2.13 $ (0.45) $ 1.85
Weighted
average common
shares issued
and
outstanding -
basic and
diluted 50,442,796 50,257,112 50,173,730 50,102,918
--------------- ------------------------- ------------------------ ------------------------ ------------------------
Gross margin -
Total [%] 46.6 % 47.0 % 46.2 % 46.3 %
Gross margin -
Services [%] 49.9 % 48.9 % 49.4 % 48.4 %
Gross margin -
Products [%] 42.2 % 44.9 % 42.1 % 43.7 %
Cryoport, Inc. and
Subsidiaries
Condensed
Consolidated
Balance Sheets
------------------ ---------------------------- ----------------------------
June 30, December 31,
---------------------------- ----------------------------
2026 2025
(in thousands) (unaudited)
------------------ ---------------------------- ----------------------------
Current assets
Cash and cash
equivalents $ 269,267 $ 250,494
------------------ ---------------------------- ----------------------------
Short-term
investments 127,426 160,714
Accounts
receivable, net 36,454 33,359
------------------ ---------------------------- ----------------------------
Inventories 21,506 23,188
Prepaid expenses
and other current
assets 5,550 8,419
------------------ ---------------------------- ----------------------------
Total current
assets 460,203 476,174
Property and
equipment, net 94,516 85,448
------------------ ---------------------------- ----------------------------
Operating lease
right-of-use
assets 40,323 39,720
Intangible assets,
net 135,992 138,082
------------------ ---------------------------- ----------------------------
Goodwill 22,068 22,400
Deposits 2,038 2,092
------------------ ---------------------------- ----------------------------
Deferred tax
assets 1,064 1,073
Total assets $ 756,204 $ 764,989
------------------ ---------------------------- ----------------------------
Current
liabilities
------------------ ---------------------------- ----------------------------
Accounts payable
and other accrued
expenses $ 16,247 $ 15,283
Accrued
compensation and
related expenses 12,186 12,980
------------------ ---------------------------- ----------------------------
Deferred revenue 1,720 943
Current portion of
operating lease
liabilities 3,937 4,133
------------------ ---------------------------- ----------------------------
Current portion of
finance lease
liabilities 448 422
Current portion of
convertible
senior notes,
net 185,687 185,094
------------------ ---------------------------- ----------------------------
Current portion of
notes payable 159 163
Current portion of
contingent
consideration 652 -
------------------ ---------------------------- ----------------------------
Total current
liabilities 221,036 219,018
Notes payable, net 985 1,087
------------------ ---------------------------- ---------------------------- Operating lease liabilities, net 40,076 39,078 Finance lease liabilities, net 726 741 ------------------ ---------------------------- ---------------------------- Deferred tax liabilities 1,850 1,354 Other long-term liabilities 832 444 ------------------ ---------------------------- ---------------------------- Contingent consideration - 629 Total liabilities 265,505 262,351 ------------------ ---------------------------- ---------------------------- Total stockholders' equity 490,699 502,638 Total liabilities and stockholders' equity $ 756,204 $ 764,989 ------------------ ---------------------------- ----------------------------
Note Regarding Use of Non-GAAP Financial Measures
To supplement our financial statements, which are presented on the basis of U.S. generally accepted accounting principles (GAAP), the following non-GAAP measure of financial performance as defined in Regulation G of the Securities Exchange Act of 1934 is included in this release: adjusted EBITDA from continuing operations. Non-GAAP financial measures are not calculated in accordance with GAAP, are not based on any comprehensive set of accounting rules or principles and may be different from non-GAAP financial measures presented by other companies. Non-GAAP financial measures, including adjusted EBITDA from continuing operations, should not be considered as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.
Adjusted EBITDA from continuing operations is defined as loss from continuing operations adjusted for net interest expense, income taxes, depreciation and amortization expense, stock-based compensation expense, acquisition and integration costs, cost reduction initiatives, investment income, unrealized (gain)/loss on investments, foreign currency loss, changes in fair value of contingent consideration and charges or gains resulting from non-recurring events, as applicable.
Management believes that adjusted EBITDA from continuing operations provides a useful measure of Cryoport's operating results, a meaningful comparison with historical results and with the results of other companies, and insight into Cryoport's ongoing operating performance. Further, management and the Company's board of directors utilize adjusted EBITDA from continuing operations to gain a better understanding of Cryoport's comparative operating performance from period to period and as a basis for planning and forecasting future periods. Adjusted EBITDA from continuing operations is also a significant performance measure used by Cryoport in connection with its incentive compensation programs. Management believes adjusted EBITDA from continuing operations, when read in conjunction with Cryoport's GAAP financials, is useful to investors because it provides a basis for meaningful period-to-period comparisons of Cryoport's ongoing operating results, including results of operations, against investor and analyst financial models, helps identify trends in Cryoport's underlying business and in performing related trend analyses, and it provides a better understanding of how management plans and measures Cryoport's underlying business.
Cryoport, Inc.
and
Subsidiaries
Reconciliation of GAAP loss from continuing operations to
adjusted EBITDA
(unaudited)
--------------- ------------------ -------------------- -------------------- ------------------
Three Months Ended Six Months Ended
June 30, June 30,
---------------------------------------- ----------------------------------------
2026 2025 2026 2025
(in thousands)
--------------- ------------------ -------------------- -------------------- ------------------
GAAP loss from
continuing
operations $ (8,255) $ (12,014) $ (17,687) $ (18,752)
Non-GAAP
adjustments to
loss:
--------------- ------------------ -------------------- -------------------- ------------------
Depreciation
and
amortization
expense 6,589 6,249 12,991 12,383
Acquisition and
integration
costs -- 30 -- 31
--------------- ------------------ -------------------- -------------------- ------------------
Cost reduction
initiatives 140 266 140 482
Investment
income (3,132) (1,466) (6,222) (3,039)
--------------- ------------------ -------------------- -------------------- ------------------
Unrealized
(gain) loss on
investments (212) 1,082 1,893 1,275
Foreign
currency loss 651 2,002 1,105 2,247
--------------- ------------------ -------------------- -------------------- ------------------
Interest
expense, net 518 618 950 1,201
Stock-based
compensation
expense 2,402 2,045 4,797 5,109
--------------- ------------------ -------------------- -------------------- ------------------
Change in fair
value of
contingent
consideration 27 -- 42 (5,178)
Income taxes 505 274 613 508
--------------- ------------------ -------------------- -------------------- ------------------
Other
adjustments 1,142 -- 1,142 --
Adjusted EBITDA
from
continuing
operations $ 375 $ (914) $ (236) $ (3,733)
--------------- ------------------ -------------------- -------------------- ------------------
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-reports-second-quarter-2026-financial-results-302845362.html
SOURCE Cryoport, Inc.